<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04319588</url>
  </required_header>
  <id_info>
    <org_study_id>20/20 PAR ComEt CBM</org_study_id>
    <nct_id>NCT04319588</nct_id>
  </id_info>
  <brief_title>Parasternal Block for Cardiac Surgery</brief_title>
  <acronym>Parasternal</acronym>
  <official_title>Parasternal Block for Postoperative Analgesia in Cardiac Surgery: a Pilot Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Campus Bio-Medico University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Campus Bio-Medico University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study examine the effect of Parasternal Intercostal Nerve Blocks with local anesthetic
      on pain control in patients undergoing non-emergent cardiac surgery in a prospective
      controlled trial. Half of participants will receive General Anesthesia combined to
      parasternal block while the other half receive only General Anesthesia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      60 patients undergoing elective cardiac surgery will be enrolled and divided into two groups:

        1. Interventional (parasternal group)

        2. Case control group The &quot;parasternal group&quot; of patients will receive the pre-operative
           parasternal block (20 ml of 0.5% Ropivacaine per side) in association with infiltration
           with local anesthetic of access to thoracic drainage (drainage infiltration with 20 ml
           of 0.25% Ropivacaine) at the end of the intervention combined to General Anesthesia.

      The &quot;case control group&quot; will only receive drainage infiltration with local anesthetic and
      standard intraoperative management with opioids.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 6, 2020</start_date>
  <completion_date type="Anticipated">May 19, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 9, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Pain Score</measure>
    <time_frame>24 hours</time_frame>
    <description>Postoperative pain assessment using the NRS scale (score from 0 to 10)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total opioids consumption</measure>
    <time_frame>24 hours</time_frame>
    <description>Number of opioid deliveries (bolus morphine) in the postoperative period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to first opioid</measure>
    <time_frame>48 hours</time_frame>
    <description>The time in minutes between awakening and the first opioid administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Respiratory performance at the TRI-FLOW</measure>
    <time_frame>24 hours</time_frame>
    <description>Respiratory performance is assessed by the number of balls raised during inspiration with the TRI-FLOW</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative opioid administration</measure>
    <time_frame>4 hours</time_frame>
    <description>Quantitative evaluation of opioids needed in the intraoperative period</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Cardiac Disease</condition>
  <condition>Analgesia</condition>
  <condition>Acute Pain</condition>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>Parasternal Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The &quot;parasternal group&quot; of patients will receive the pre-operative parasternal block (20 ml of 0.5% Ropivacaine per side) in association with infiltration with local anesthetic of access to thoracic drainage (drainage infiltration with 20 ml of 0.25% Ropivacaine) at the end of the intervention combined to General Anesthesia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Case control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The &quot;case control group&quot; will only receive drainage infiltration with local anesthetic and standard intraoperative management with opioids.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Parasternal Block+ Infiltration with local anesthetic of access to thoracic drainage</intervention_name>
    <description>After induction of general anesthesia we will perform an ultrasound-guided Parasternal Block in association with infiltration with local anesthetic of access to thoracic drainage at the end of the intervention.</description>
    <arm_group_label>Parasternal Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Infiltration with local anesthetic of access to thoracic drainage</intervention_name>
    <description>Infiltration with local anesthetic of access to thoracic drainage at the end of the intervention.</description>
    <arm_group_label>Case control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing elective cardiac surgery

          -  Age over 18 years

          -  ASA I-IV

          -  Approval by the patient of informed consent

        Exclusion Criteria:

          -  Allergy to local anesthetics

          -  Puncture site infection

          -  Lack of signing of informed consent

          -  Weight &lt;30 Kg

          -  Age &lt;18 years

          -  Emergency interventions

          -  ASA &gt; IV

          -  Sternal dehiscences

          -  Dementia (for difficulties in managing weaning from mechanical ventilation and pain)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Giulia Nonnis</last_name>
    <phone>3382752818</phone>
    <email>g.nonnis@unicampus.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Campus Biomedico University</name>
      <address>
        <city>Rome</city>
        <state>Roma</state>
        <zip>00128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giulia Nonnis, MD</last_name>
      <phone>3382752818</phone>
      <email>g.nonnis@unicampus.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Chou R, Gordon DB, de Leon-Casasola OA, Rosenberg JM, Bickler S, Brennan T, Carter T, Cassidy CL, Chittenden EH, Degenhardt E, Griffith S, Manworren R, McCarberg B, Montgomery R, Murphy J, Perkal MF, Suresh S, Sluka K, Strassels S, Thirlby R, Viscusi E, Walco GA, Warner L, Weisman SJ, Wu CL. Management of Postoperative Pain: A Clinical Practice Guideline From the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists' Committee on Regional Anesthesia, Executive Committee, and Administrative Council. J Pain. 2016 Feb;17(2):131-57. doi: 10.1016/j.jpain.2015.12.008. Erratum in: J Pain. 2016 Apr;17(4):508-10. Dosage error in article text.</citation>
    <PMID>26827847</PMID>
  </results_reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 9, 2020</study_first_submitted>
  <study_first_submitted_qc>March 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2020</study_first_posted>
  <last_update_submitted>March 21, 2020</last_update_submitted>
  <last_update_submitted_qc>March 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Campus Bio-Medico University</investigator_affiliation>
    <investigator_full_name>Giulia Nonnis</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Acute Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Anesthetics, Local</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

